JP2025505200A - Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法 - Google Patents

Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法 Download PDF

Info

Publication number
JP2025505200A
JP2025505200A JP2024546424A JP2024546424A JP2025505200A JP 2025505200 A JP2025505200 A JP 2025505200A JP 2024546424 A JP2024546424 A JP 2024546424A JP 2024546424 A JP2024546424 A JP 2024546424A JP 2025505200 A JP2025505200 A JP 2025505200A
Authority
JP
Japan
Prior art keywords
groups
alkyl
optionally substituted
independently selected
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505200A5 (cg-RX-API-DMAC7.html
Inventor
ティモシー ジェイ. センター,
レスリー エー. デーキン,
エレナ ドルギフ,
ジェシカ エイチ. オルセン,
アキラ ジェイ. シミズ,
スティーブン ディー. ストーン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2025505200A publication Critical patent/JP2025505200A/ja
Publication of JP2025505200A5 publication Critical patent/JP2025505200A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024546424A 2022-02-08 2023-02-08 Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法 Pending JP2025505200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307933P 2022-02-08 2022-02-08
US63/307,933 2022-02-08
PCT/US2023/012579 WO2023154310A1 (en) 2022-02-08 2023-02-08 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Publications (2)

Publication Number Publication Date
JP2025505200A true JP2025505200A (ja) 2025-02-21
JP2025505200A5 JP2025505200A5 (cg-RX-API-DMAC7.html) 2026-02-04

Family

ID=85570218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546424A Pending JP2025505200A (ja) 2022-02-08 2023-02-08 Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法

Country Status (7)

Country Link
US (1) US20250163021A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476199A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505200A (cg-RX-API-DMAC7.html)
CN (1) CN118984821A (cg-RX-API-DMAC7.html)
AU (1) AU2023219516A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251230A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154310A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) * 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (en) * 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
CN106749330A (zh) * 2016-12-29 2017-05-31 长春海谱润斯科技有限公司 一种杂环衍生物及使用该杂环衍生物的有机发光器件
US20220144838A1 (en) * 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
CA3171950A1 (en) * 2020-04-22 2021-10-28 David William Sheppard Collagen 1 translation inhibitors and methods of use thereof
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
WO2023154310A1 (en) 2023-08-17
AU2023219516A1 (en) 2024-08-22
CN118984821A (zh) 2024-11-19
CA3251230A1 (en) 2023-08-17
US20250163021A1 (en) 2025-05-22
EP4476199A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
AU2023219516A1 (en) 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
CN110352188B (zh) 氟代烯丙胺衍生物及其用途
US4758568A (en) Quinoline therapeutic agents
EP3788039B1 (en) Factor xiia inhibitors
JP2024544060A (ja) Apol1のスピロ環式阻害剤およびこれを使用する方法
US12612379B2 (en) Inhibitors of APOL1 and methods of using same
JP2025505644A (ja) Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法
CA3179333A1 (en) Modulators of alpha-1 antitrypsin
JP2025505645A (ja) Apol1の阻害剤としてのスピロピペリジン誘導体およびその使用方法
CN114206871B (zh) 1-(6-(甲氧基)哒嗪-3-基)环丙烷-1-甲酰胺衍生物作为自分泌运动因子(atx)调节剂治疗发炎性气道疾病
WO2021013833A1 (en) N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases
AU2022246108A1 (en) Indoline derivatives as ddr1 and ddr2 inhibitors
OA21973A (en) 4-Phenyl-2-(1H-1,2,3-Triazol-4-YL) Piperidin-4-OL derivatives as inhibitors Of APOL1 and methods of using same.
CN118574809A (zh) 作为apol1抑制剂的4-苯基-2-(1h-1,2,3-三唑-4-基)哌啶-4-醇衍生物和其使用方法
AU2024301644A1 (en) Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity
EA053250B1 (ru) Производные 4-фенил-2-(1h-1,2,3-триазол-4-ил)пиперидин-4-ола в качестве ингибиторов apol1 и способы их применения
HK40048874B (en) Factor xiia inhibitors
HK40048874A (en) Factor xiia inhibitors
TW201514162A (zh) 作爲鉀離子通道抑制劑之呔
CN105878243A (zh) 吡非尼酮衍生物在制药中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260127